Effect of nicorandil treatment adjunctive to percutaneous coronary intervention in patients with acute myocardial infarction: a systematic review and meta-analysis
| Autor: | Peng Li, Jing Xu, Jin Zhou, Shan Sun, Bingwei Chen, Aijuan Cheng |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Medicine (General)
medicine.medical_specialty no-reflow phenomenon medicine.medical_treatment Myocardial Infarction Acute myocardial infarction 030204 cardiovascular system & hematology Biochemistry Ventricular Function Left 03 medical and health sciences Percutaneous Coronary Intervention R5-920 0302 clinical medicine Internal medicine medicine Humans In patient cardiovascular diseases 030212 general & internal medicine Myocardial infarction Nicorandil Ventricular function business.industry Meta Analysis Biochemistry (medical) Percutaneous coronary intervention Stroke Volume Cell Biology General Medicine medicine.disease major adverse cardiovascular events Meta-analysis Conventional PCI No reflow phenomenon cardiovascular system Cardiology ventricular function business medicine.drug |
| Zdroj: | Journal of International Medical Research, Vol 48 (2020) The Journal of International Medical Research |
| ISSN: | 1473-2300 0300-0605 |
| Popis: | Objective There is controversy whether nicorandil treatment has cardioprotective effects in patients with acute myocardial infarction (AMI) following percutaneous coronary intervention (PCI). This meta-analysis was conducted to assess the efficacy of nicorandil on functional and clinical outcomes after PCI. Methods Systematic databases were searched to retrieve studies that compared the effect of nicorandil with a control group in patients with AMI who underwent PCI. Outcomes related to coronary blood flow, and functional and clinical outcomes were extracted and a meta-analysis was performed. Trial sequential analysis was conducted to estimate the required sample size for statistical power. Results Twenty-four trials involving 2965 patients with AMI were enrolled. Pooled results showed that nicorandil treatment significantly suppressed the incidence of no-reflow phenomenon and reperfusion arrhythmia after reperfusion, improved the left ventricular ejection fraction and left ventricular end-systolic volume index, and reduced major adverse cardiovascular events and cardiovascular death. Trial sequential analysis confirmed the effect of nicorandil in reducing the incidence of no-reflow phenomenon and follow-up major adverse cardiovascular events in patients with AMI after PCI. Conclusion Our findings suggest that nicorandil treatment adjunctive to reperfusion therapy improves myocardial reperfusion, cardiac function, and clinical outcomes in patients with AMI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|